Moritz Mirna

Safety of the oral factor XIa inhibitor asundexian compared with apixaban in patients with atrial fibrillation (PACIFIC-AF): a multicentre, randomised, double-blind, double-dummy, dose-finding phase 2 study

Jonathan P. Piccini, Valeria Caso, Stuart J. Connolly et al. · The Lancet · 2022 · 311 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +11

Vericiguat in patients with chronic heart failure and reduced ejection fraction (VICTOR): a double-blind, placebo-controlled, randomised, phase 3 trial

Javed Butler, Ciaran J. McMullan, Kevin J. Anstrom et al. · The Lancet · 2025 · 64 citations · Full text

Medicine, Cardiology, Internal Medicine +12

Neutrophil-to-lymphocyte ratio and monocyte-to-lymphocyte ratio predict length of hospital stay in myocarditis

Moritz Mirna, Lukas Schmutzler, Albert Topf et al. · Scientific Reports · 2021 · 58 citations · Full text

Medicine, Cardiology, Internal Medicine +13

Analysis of Novel Cardiovascular Biomarkers in Patients With Pulmonary Hypertension (PH)

Moritz Mirna, Ilonka Rohm, Peter Jirak et al. · Heart Lung and Circulation · 2019 · 37 citations

Medicine, Cardiology, Internal Medicine +11

Vericiguat for patients with heart failure and reduced ejection fraction across the risk spectrum: an individual participant data analysis of the VICTORIA and VICTOR trials

Faı̈ez Zannad, Christopher M. O’Connor, Javed Butler et al. · The Lancet · 2025 · 32 citations · Full text

Pharmacy, Cardiology, Pharmacotherapy +17